STOCK TITAN
  1. Home
  2. Sec-filings
  3. RCUS
  4. [SCHEDULE 13D/A] Arcus Biosciences, Inc. SEC Filing

[SCHEDULE 13D/A] Arcus Biosciences, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock RCUS logo
Arcus Bioscience

NYSE:RCUS

RCUS Rankings

#2561 Ranked by Market Cap
N/A Ranked by Dividends

RCUS Latest News

Sep 2, 2025
Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation
Aug 20, 2025
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
Aug 6, 2025
Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update
Jul 24, 2025
Arcus Biosciences Announces New Employment Inducement Grants
Jul 10, 2025
Arcus Biosciences’ Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer

RCUS Latest SEC Filings

Aug 6, 2025
[10-Q] Arcus Biosciences, Inc. Quarterly Earnings Report

RCUS Stock Data

1.13B
69.33M
34.76%
67.52%
8.43%
Biotechnology
Pharmaceutical Preparations
Link
United States
HAYWARD